---
title: "Legend Biotech Corporation (LEGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LEGN.US.md"
symbol: "LEGN.US"
name: "Legend Biotech Corporation"
industry: "Biotechnology"
datetime: "2026-04-15T06:43:34.801Z"
locales:
  - [en](https://longbridge.com/en/quote/LEGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LEGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LEGN.US.md)
---

# Legend Biotech Corporation (LEGN.US)

## Company Overview

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [legendbiotech.com](https://legendbiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:15.000Z

**Overall: C (0.45)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 92 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 64.02% |  |
| Net Profit YoY | -67.68% |  |
| P/B Ratio | 3.45 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3456588108.96 |  |
| Revenue | 1028900000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -29.06% | E |
| Profit Margin | -28.85% | E |
| Gross Margin | 20.03% | D |
| Revenue YoY | 64.02% | A |
| Net Profit YoY | -67.68% | E |
| Total Assets YoY | 3.80% | C |
| Net Assets YoY | -3.70% | D |
| Cash Flow Margin | 33.76% | C |
| OCF YoY | 64.02% | A |
| Turnover | 0.60 | B |
| Gearing Ratio | 42.20% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Legend Biotech Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "64.02%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-67.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.45",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3456588108.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1028900000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-29.06%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-28.85%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "20.03%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "64.02%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-67.68%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.80%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.70%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "33.76%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "64.02%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.60",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "42.20%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.65 | 463/393 | - | - | - |
| PB | 3.45 | 263/393 | 6.27 | 5.63 | 3.53 |
| PS (TTM) | 3.36 | 75/393 | 9.02 | 7.40 | 3.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | C | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-14T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 56% |
| Overweight | 5 | 31% |
| Hold | 2 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.69 |
| Highest Target | 86.00 |
| Lowest Target | 21.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LEGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LEGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LEGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LEGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**